Brazil's health regulator has denied permission to import Covaxin, the coronavirus vaccine developed indigenously by Indian pharma firm Bharat Biotech. According to reports, a Brazilian government gazette had said that Covaxin had been rejected "considering the non-compliance with the requirements of Good Manufacturing Practices for Medicines''.

In its response to the same, Bharat Biotech told NDTV: ''The requirements pointed out during inspection will be fulfilled, the timelines for fulfillment is under discussion with the Brazil NRA and will be resolved soon.''

Bharat Biotech's indigenous vaccine Covaxin has have been developed in collaboration with the Indian Council for Medical Research.

It was approved for emergency use by the  Drugs Controller General of India (DCGI) in January.

Covaxin has been declared to be an 81 percent success during the Phase 3 clinical trials in India.

Bharat Biotech said the vaccine is effective against the UK variant of the virus.